Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

• Cytologically or histologic confirmed non-small cell lung cancer, stage IIIB or IV or recurrent after primary surgery or radiotherapy.
• ECOG PS 0-1
• 70 years of age or older
• Must have measurable disease
• ANC > 1500, platelets > 100,000
• Total bilirubin </= 1.5, SGOT * SGPT < 5 x ULN
• Able and willing to swallow and absorb oral medication
• Able and willing to sign consent
• Request archival diagnostic tissue for EGFR expression but not required

Exclusion Criteria:

• Proteinuria as demonstrated by UPC ratio >/= 1.0
• Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent (includes thalidomide)
• Prior treatment for advanced stage disease, with the exception of surgery or radiation (no systemic)
• History of gross hemoptysis within 1 month of enrollment unless treated with surgery or radiation
• Evidence of bleeding diathesis or coagulopathy or other serious/acute internal bleeding within 6 months of enrollment.
• Current, ongoing treatment with full dose warfarin or equivalent
• Current(within 10 days)use of aspirin (> 325mg/day) or other NSAID with antiplatelet activity
• History of hemorrhagic or thrombotic stoke, TIA, or other CNS bleeding w/in last 6 months. Clinically significant PVD
• Known CNS disease except for treated brain mets.
• Squamous cell histology
• Blood pressure > 150/100 that cannot be ameliorated with standard anti-hypertensives
• History of hypertensive crisis or hypertensive encephalopathy
• NYHA grade II or > CHF
• History of MI within 6 months of enrollment
• Major surgery, open biopsy, significant trauma within 28 days of enrollment
• Pregnancy, lactation
• Abdominal or other fistula, abcess, perforation